GERON CORP Debt Securities, Available-for-sale
GERON CORP (GERN) had Debt Securities, Available-for-sale of $422.07 million as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2025-02-27
- 2024-12-31: Debt Securities, Available-for-sale $422.07M.
- 2024-09-30: Debt Securities, Available-for-sale $316.74M.
- 2024-06-30: Debt Securities, Available-for-sale $312.29M.
- 2024-03-31: Debt Securities, Available-for-sale $274.07M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2024-12-31 | $422.07M 10-K · filed 2025-02-27 |
| 2024-09-30 | $316.74M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $312.29M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $274.07M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $306.97M 10-K · filed 2025-02-27 |
| 2023-09-30 | $350.64M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $342.76M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $296.06M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $115.90M 10-K · filed 2024-02-28 |
| 2022-09-30 | $133.68M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $143.23M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $146.29M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $177.50M 10-K · filed 2023-03-16 |
| 2021-09-30 | $186.45M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $181.48M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $212.78M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $249.74M 10-K · filed 2022-03-10 |
| 2020-09-30 | $228.44M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $242.10M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $112.85M 10-Q · filed 2020-05-28 |
| 2019-12-31 | $145.33M 10-K · filed 2021-03-11 |
| 2019-09-30 | $138.26M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $144.28M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $163.05M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $171.30M 10-K · filed 2020-03-12 |
| 2018-09-30 | $171.76M 10-Q · filed 2018-11-01 |
| 2017-12-31 | $92.59M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |